Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Scott Waldman and Adam Snook.
Connection Strength

12.854
  1. Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer. 2019 Apr 23; 7(1):104.
    View in: PubMed
    Score: 0.819
  2. Snook AE, Baybutt TR, Hyslop T, Waldman SA. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. Hum Gene Ther Methods. 2016 Dec; 27(6):238-250.
    View in: PubMed
    Score: 0.694
  3. Snook AE, Magee MS, Schulz S, Waldman SA. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol. 2014 Jul; 44(7):1956-66.
    View in: PubMed
    Score: 0.582
  4. Snook AE, Waldman SA. Advances in cancer immunotherapy. Discov Med. 2013 Feb; 15(81):120-5.
    View in: PubMed
    Score: 0.532
  5. Snook AE, Magee MS, Waldman SA. GUCY2C-targeted cancer immunotherapy: past, present and future. Immunol Res. 2011 Dec; 51(2-3):161-9.
    View in: PubMed
    Score: 0.490
  6. Snook AE, Magee MS, Marszalowicz GP, Schulz S, Waldman SA. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. Cancer Immunol Immunother. 2012 May; 61(5):713-23.
    View in: PubMed
    Score: 0.488
  7. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009 Apr 15; 69(8):3537-44.
    View in: PubMed
    Score: 0.408
  8. Snook AE, Waldman SA. CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS. Bioforum Eur. 2009; 3:14-16.
    View in: PubMed
    Score: 0.401
  9. Snook AE, Huang L, Schulz S, Eisenlohr LC, Waldman SA. Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens. Clin Transl Sci. 2008 Dec; 1(3):263-4.
    View in: PubMed
    Score: 0.398
  10. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008 Jul 2; 100(13):950-61.
    View in: PubMed
    Score: 0.387
  11. Snook AE, Stafford BJ, Eisenlohr LC, Rothstein JL, Waldman SA. Mucosally restricted antigens as novel immunological targets for antitumor therapy. Biomark Med. 2007 Jun; 1(1):187-202.
    View in: PubMed
    Score: 0.359
  12. Crutcher MM, Baybutt TR, Kopenhaver JS, Snook AE, Waldman SA. Emerging drug targets for colon cancer: A preclinical assessment. Expert Opin Ther Targets. 2022 Feb 10; 1-10.
    View in: PubMed
    Score: 0.249
  13. Rappaport JA, Entezari AA, Caspi A, Caksa S, Jhaveri AV, Stanek TJ, Ertel A, Kupper J, Fortina PM, McMahon SB, Jaynes JB, Snook AE, Waldman SA. A ß-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer. Cell Mol Gastroenterol Hepatol. 2021 Dec 22.
    View in: PubMed
    Score: 0.246
  14. Entezari AA, Snook AE, Waldman SA. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert Opin Ther Targets. 2021 May; 25(5):335-346.
    View in: PubMed
    Score: 0.238
  15. Kopenhaver J, Crutcher M, Waldman SA, Snook AE. The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission. Expert Opin Biol Ther. 2021 Oct; 21(10):1335-1345.
    View in: PubMed
    Score: 0.237
  16. Cheslow L, Snook AE, Waldman SA. Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers. Biomark Med. 2021 06; 15(8):597-608.
    View in: PubMed
    Score: 0.236
  17. Zalewski A, Snook AE, Waldman SA. Stem cells as therapeutic targets in colorectal cancer. Per Med. 2021 Mar; 18(2):171-183.
    View in: PubMed
    Score: 0.232
  18. Lisby AN, Flickinger JC, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev. 2021; 6(2):117-129.
    View in: PubMed
    Score: 0.232
  19. Barton JR, Snook AE, Waldman SA. From leptin to lasers: the past and present of mouse models of obesity. Expert Opin Drug Discov. 2021 Jan 29; 1-14.
    View in: PubMed
    Score: 0.231
  20. Flickinger JC, Rappaport JA, Barton JR, Baybutt TR, Pattison AM, Snook AE, Waldman SA. Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. Biomark Med. 2021 Feb; 15(3):201-217.
    View in: PubMed
    Score: 0.231
  21. Flickinger JC, Singh J, Carlson R, Leong E, Baybutt TR, Barton J, Caparosa E, Pattison A, Rappaport JA, Roh J, Zhan T, Bashir B, Waldman SA, Snook AE. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. J Immunother Cancer. 2020 Aug; 8(2).
    View in: PubMed
    Score: 0.224
  22. Pattison AM, Barton JR, Entezari AA, Zalewski A, Rappaport JA, Snook AE, Waldman SA. Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity. Cancer Biol Ther. 2020 Jun 28; 1-7.
    View in: PubMed
    Score: 0.222
  23. Blomain ES, Rappaport JA, Pattison AM, Bashir B, Caparosa E, Stem J, Snook AE, Waldman SA. APC-ß-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. Cancer Biol Ther. 2020 Feb 09; 1-11.
    View in: PubMed
    Score: 0.216
  24. Caparosa EM, Stem J, Snook AE, Waldman SA. Biomarker targeting of colorectal cancer stem cells. Biomark Med. 2019 Aug; 13(11):891-894.
    View in: PubMed
    Score: 0.209
  25. Stem J, Flickinger JC, Merlino D, Caparosa EM, Snook AE, Waldman SA. Therapeutic targeting of gastrointestinal cancer stem cells. Regen Med. 2019 Apr 26.
    View in: PubMed
    Score: 0.205
  26. Bashir B, Merlino DJ, Rappaport JA, Gnass E, Palazzo JP, Feng Y, Fearon ER, Snook AE, Waldman SA. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated and MSI colorectal neoplasia. Hum Pathol. 2019 Feb 01.
    View in: PubMed
    Score: 0.202
  27. Abraham TS, Flickinger JC, Waldman SA, Snook AE. TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C. J Immunol. 2019 Feb 15; 202(4):1301-1310.
    View in: PubMed
    Score: 0.201
  28. Magee MS, Abraham TS, Baybutt TR, Flickinger JC, Ridge NA, Marszalowicz GP, Prajapati P, Hersperger AR, Waldman SA, Snook AE. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res. 2018 Apr 03.
    View in: PubMed
    Score: 0.190
  29. Kraft CL, Rappaport JA, Snook AE, Pattison AM, Lynch JP, Waldman SA. GUCY2C maintains intestinal LGR5+ stem cells by opposing ER stress. Oncotarget. 2017 Nov 28; 8(61):102923-102933.
    View in: PubMed
    Score: 0.185
  30. Li P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop TM, Waldman SA. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Res. 2017 Sep 15; 77(18):5095-5106.
    View in: PubMed
    Score: 0.183
  31. Li P, Lin JE, Snook AE, Waldman SA. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice. Toxins (Basel). 2017 Sep 12; 9(9).
    View in: PubMed
    Score: 0.183
  32. Aka AA, Rappaport JA, Pattison AM, Sato T, Snook AE, Waldman SA. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert Rev Clin Pharmacol. 2017 May; 10(5):549-557.
    View in: PubMed
    Score: 0.178
  33. Xiang B, Baybutt TR, Berman-Booty L, Magee MS, Waldman SA, Alexeev VY, Snook AE. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. J Immunol. 2017 May 01; 198(9):3507-3514.
    View in: PubMed
    Score: 0.177
  34. Pattison AM, Blomain ES, Merlino DJ, Wang F, Crissey MA, Kraft CL, Rappaport JA, Snook AE, Lynch JP, Waldman SA. Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. Infect Immun. 2016 Oct; 84(10):3083-91.
    View in: PubMed
    Score: 0.171
  35. Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology. 2016; 5(10):e1227897.
    View in: PubMed
    Score: 0.170
  36. Blomain ES, Merlino DJ, Pattison AM, Snook AE, Waldman SA. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer. Mol Pharmacol. 2016 Sep; 90(3):199-204.
    View in: PubMed
    Score: 0.168
  37. Lin JE, Colon-Gonzalez F, Blomain E, Kim GW, Aing A, Stoecker B, Rock J, Snook AE, Zhan T, Hyslop TM, Tomczak M, Blumberg RS, Waldman SA. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. Cancer Res. 2016 Jan 15; 76(2):339-46.
    View in: PubMed
    Score: 0.163
  38. Marszalowicz GP, Snook AE, Magee MS, Merlino D, Berman-Booty LD, Waldman SA. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. Oncotarget. 2014 Oct 15; 5(19):9460-71.
    View in: PubMed
    Score: 0.150
  39. Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T, Waldman SA. The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2328-37.
    View in: PubMed
    Score: 0.149
  40. Witek ME, Snook AE, Lin JE, Blomain ES, Xiang B, Magee M, Waldman SA. A Novel CDX2 Isoform Regulates Alternative Splicing. PLoS One. 2014; 9(8):e104293.
    View in: PubMed
    Score: 0.148
  41. Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. Tumor Radiation Therapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C. Int J Radiat Oncol Biol Phys. 2014 Apr 1; 88(5):1188-95.
    View in: PubMed
    Score: 0.144
  42. Gibbons AV, Lin JE, Kim GW, Marszalowicz GP, Li P, Stoecker BA, Blomain ES, Rattan S, Snook AE, Schulz S, Waldman SA. Intestinal GUCY2C Prevents TGF-ß Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer. Cancer Res. 2013 Nov 15; 73(22):6654-66.
    View in: PubMed
    Score: 0.139
  43. Blomain ES, Lin JE, Kraft CL, Trela UT, Rock JM, Aing AS, Snook AE, Waldman SA. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert Rev Clin Pharmacol. 2013 Sep; 6(5):557-64.
    View in: PubMed
    Score: 0.138
  44. Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal cancer immunotherapy. Discov Med. 2013 May; 15(84):301-8.
    View in: PubMed
    Score: 0.135
  45. Magee MS, Snook AE, Marszalowicz GP, Waldman SA. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomark Med. 2013 Feb; 7(1):23-35.
    View in: PubMed
    Score: 0.133
  46. Lin JE, Snook AE, Li P, Stoecker BA, Kim GW, Magee MS, Garcia AV, Valentino MA, Hyslop T, Schulz S, Waldman SA. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One. 2012; 7(2):e31686.
    View in: PubMed
    Score: 0.125
  47. Valentino MA, Lin JE, Snook AE, Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S, Waldman SA. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest. 2011 Sep; 121(9):3578-88.
    View in: PubMed
    Score: 0.120
  48. Lin JE, Valentino M, Marszalowicz G, Magee MS, Li P, Snook AE, Stoecker BA, Chang C, Waldman SA. Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics. Toxins (Basel). 2010 Aug; 2(8):2028-54.
    View in: PubMed
    Score: 0.112
  49. Lin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, Pitari GM, Waldman SA. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology. 2010 Jan; 138(1):241-54.
    View in: PubMed
    Score: 0.105
  50. Gong L, Debruyne PR, Witek M, Nielsen K, Snook A, Lin JE, Bombonati A, Palazzo J, Schulz S, Waldman SA. Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis. Clin Transl Sci. 2009 Aug; 2(4):286-93.
    View in: PubMed
    Score: 0.104
  51. Chang C, Marszlowicz G, Waldman Z, Li P, Snook AE, Lin JE, Schulz S, Waldman SA. Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer. Biomark Med. 2009 Feb; 3(1):33-45.
    View in: PubMed
    Score: 0.101
  52. Chen T, Lin R, Avula L, Sarker R, Yang J, Cha B, Tse CM, McNamara G, Seidler U, Waldman S, Snook A, Bijvelds MJC, de Jonge HR, Li X, Donowitz M. NHERF3 is Necessary for E. coli Heat Stable Enterotoxin (ST)-induced Inhibition of NHE3 - Differences in Signaling in Mouse Small Intestine and Caco-2 Cells. Am J Physiol Cell Physiol. 2019 Jul 31.
    View in: PubMed
    Score: 0.052
  53. Krishnan V, Xu X, Kelly D, Snook A, Waldman SA, Mason RW, Jia X, Rajasekaran AK. CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia. Mol Pharm. 2015 Jun 1; 12(6):2101-11.
    View in: PubMed
    Score: 0.039
  54. Plesa G, Snook AE, Waldman SA, Eisenlohr LC. Derivation and fluidity of acutely induced dysfunctional CD8+ T cells. J Immunol. 2008 Apr 15; 180(8):5300-8.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.